Welcome to our dedicated page for ZyVersa Therapeutics news (Ticker: ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics stock.
ZyVersa Therapeutics, Inc. (ZVSA) generates a steady flow of news related to its progress as a clinical-stage specialty biopharmaceutical company focused on renal and inflammatory diseases. Company press releases and SEC filings highlight developments around its two proprietary platforms: Cholesterol Efflux Mediator™ VAR 200 for kidney diseases and Inflammasome ASC Inhibitor IC 100 for chronic inflammatory and cardiometabolic conditions.
News coverage for ZyVersa frequently centers on clinical and preclinical milestones. For VAR 200, investors can follow announcements about the initiation and conduct of a phase 2a proof-of-concept trial in patients with diabetic kidney disease, plans for subsequent studies in focal segmental glomerulosclerosis and Alport syndrome, and use of VAR 200 under FDA-authorized Emergency Compassionate Use in a patient with ApoCII amyloidosis. Releases also discuss preclinical data showing reduced renal lipid accumulation, protection against renal injury and fibrosis, and improvement in proteinuria in multiple kidney disease models.
For IC 100, ZyVersa issues news highlighting preclinical data in cardiometabolic and neurological models, including effects on insulin resistance, vascular inflammation, and cardiac function, as well as plans for IND-enabling studies in a diet-induced obesity model and a future phase 1 trial in overweight subjects at risk for cardiometabolic conditions. The company also reports on scientific publications and review articles that, in its view, support the rationale for targeting inflammasomes and renal lipotoxicity.
Another recurring theme in ZyVersa’s news is corporate and capital markets activity. Releases describe equity purchase agreements, warrant inducement transactions, and financing arrangements intended to fund ongoing research and development, along with updates on its trading status following the delisting of its common stock from Nasdaq and quotation on the OTCQB Venture Market under the symbol ZVSA.
By monitoring this news page, readers can track ZyVersa’s reported clinical progress, preclinical findings, financing events, and regulatory and listing updates, all drawn from the company’s own press releases and related disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ZyVersa Therapeutics (Nasdaq: ZVSA) announced a public offering of 11,015,500 shares of common stock and warrants, priced at $1.00 per share, aiming for gross proceeds of approximately $11.0 million. The offering is expected to close around April 28, 2023, contingent on customary conditions. Proceeds will primarily be used for redeeming PIPE shares, covering offering expenses, and general corporate purposes. A.G.P./Alliance Global Partners is the lead placement agent, while The Benchmark Company acts as a co-placement agent. This offering follows their SEC registration statement effective on April 26, 2023.
On April 25, 2023, ZyVersa Therapeutics (Nasdaq: ZVSA) announced the publication of a research article in the Journal of Neuroinflammation highlighting ASC specks as a therapeutic target for Parkinson's disease (PD). The study's findings indicate a direct relationship between ASC protein levels and misfolded α-synuclein aggregates in PD models, suggesting that ASC specks contribute to the progression of PD pathology. Key results include enhanced NLRP3 inflammasome activation and accelerated degeneration of dopaminergic neurons linked to ASC specks. ZyVersa's proprietary monoclonal antibody, IC 100, aims to inhibit this inflammation and has demonstrated potential benefits in various CNS and inflammatory diseases. The company continues to advance its therapeutic pipeline focusing on innovative treatments for significant unmet medical needs.